ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

University Professors in Japan Published Protocol for Production of Homogeneous iPSC Spheroids and Microtissues Using the Suction Technique with CoorsTek’s 3D Cell Culture Substrata CERAHIVE®

TOKYO, JAPAN - July 17, 2025 - 12:00 AM Mountain Time -Shugo Tohyama, professor at Fujita Medical Innovation Center (FMiC), Fujita Health University in Tokyo, project leader at Kanagawa Institute of Industrial and Science Technology (KISTEC), and team leader at Keio University Regenerative Medicine Research Center, and Taijun Moriwaki, assistant professor at FMiC, Fujita Health University in Tokyo, KISTEC, along with others recently published a research paper in the Cell Press journal ‘’STAR Protocols’’, jointly describing a protocol for production of homogeneous iPSC spheroids and microtissues using the suction technique with 3D cell culture substrata CERAHIVE® developed by CoorsTek (Japan headquarters: Shinagawa-ku, Tokyo, Japan).

This research paper details the development of CERAHIVE® culture technology, which allows for producing homogeneous uniform induced pluripotent stem cell (iPSC) spheroids and microtissues by aspirating media from cell suspensions and rapidly aggregating cells.

3D cell cultures will play an increasingly important role in disease modeling, drug efficacy evaluation, and toxicity testing. Researchers have discovered numerous advantages from innovative 3D tissue engineering methods, including increased efficiency, improved functionality, homogeneity, and spheroidization. The scalability of these methods also paves the way for mass production of these 3D structures, making them a valuable resource in regenerative medicine and drug discovery.

 

"The CERAHIVE® platform is a nice example of how we are supporting the rapid advancements in bio-medical research," said Randel Mercer, chief technology officer at CoorsTek. "We congratulate the dedicated teams at Fujita Health University, KISTEC and Keio University for utilizing our products to publish this research and look forward to future developments accelerating regenerative medicine.”  

Please visit the following URL for the newly published research paper.
https://star-protocols.cell.com/protocols/4274

About CoorsTek
Founded in 1910, CoorsTek is a leading global manufacturer of advanced materials. By leveraging expertise in engineering and materials science, CoorsTek provides solutions to complex technical challenges in the semiconductormedicalaerospace, and other industries. With over 400 proprietary formulations, vertically integrated systems, and unparalleled process capabilities, CoorsTek partners with its customers to make the world measurably better.

Media Contact: 

Nobuko Matsumoto
Communications, CoorsTek (Japan)
nobuko_matsumoto@coorstek.com

+81-3-5437-6182

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.